ASCO GI 2024 | MONTBLANC: sequential or up-front durvalumab, tremelimumab, + bevacizumab in unresectable HCC

Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy, discusses the ongoing MONTBLANC study (NCT05844046), a Phase II trial assessing the efficacy of combinations of durvalumab, tremelimumab, and bevacizumab in patients with advanced hepatocellular carcinoma (HCC). The trial explores the concept of up-front triple treatment and treatment escalation based on early radiological response rather than progression. Patients are randomized to either an early escalation arm or a triple treatment arm, with the primary endpoint being overall response rate (ORR). This study aims to provide insights into the effectiveness and safety of this novel treatment approach in advanced HCC. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.